Proven Results With ORIAHNN

See how ORIAHNN was studied in women like you

ORIAHNN is an oral treatment proven to help lighten heavy periods due to uterine fibroids

ORIAHNN was studied in two 6-month clinical trials, including premenopausal women aged 25-53 with heavy periods due to uterine fibroids.

~7 in 10

women experienced lighter periods taking ORIAHNN*

This meant bleeding volume was reduced by at least 50% from the start of the trial, and to below 80 mL (about 1/3 of a cup) at the final month of treatment.

*Compared with about 1 in 10 women taking placebo.

Measuring cup depicting that the average menstrual bleeding while taking ORIAHNN® was reduced by about 89%.

Average period bleeding was reduced by 89% (-188 mL) at Month 6

ORIAHNN values from the start of Trial 2 to Month 6 compared with an increase of about 9% (12 mL) in women taking placebo.

From the start of Trial 1 to Month 6, average bleeding was reduced by about 81% (189 mL) compared with an average decrease of about 3% (9 mL) in women taking placebo.

Measuring cup depicting the amount of menstrual bleeding at the start of the ORIAHNN® clinical trial.
Start of Trial

before starting ORIAHNN

228 mL

Measuring cup depicting menstrual bleeding after month 1 of the ORIAHNN® clinical trial.
51%
Month 1

after taking ORIAHNN for 1 month

-122 mL

Measuring cup depicting menstrual bleeding after month 3 of the ORIAHNN® clinical trial.
86%
Month 3

after taking ORIAHNN for 3 months

-194 mL

Measuring cup depicting menstrual bleeding after month 6 of the ORIAHNN® clinical trial.
89%
Month 6

after taking ORIAHNN for 6 months

-188 mL

ORIAHNN values for Trial 2. Placebo values were 256 mL at the start of the trial and resulted in 6% (16 mL) average decrease at Month 1, 12% (27 mL) average decrease at Month 3, and 9% (12 mL) average increase at Month 6.

For Trial 1, ORIAHNN values were 238 mL at the start of the trial and resulted in a 52% (124 mL) average decrease at Month 1, 82% (187 mL) average decrease at Month 3, and 81% (189 mL) average decrease at Month 6. Placebo values were 259 mL at the start of the trial and resulted in 13% (33 mL) average decrease at Month 1, 4% (0.1 mL) average decrease at Month 3, and 3% (9 mL) average decrease at Month 6.

5 in 10 women

taking ORIAHNN for 6 months saw an increase in their hemoglobin levels.§

5 in 10 women

taking ORIAHNN for 6 months saw an
increase in their hemoglobin levels.§

Before starting ORIAHNN, 100 women in the 2 ORIAHNN clinical trials had low levels of hemoglobin, which can be a sign of anemia. Most of these women (90%) also took an iron supplement. ORIAHNN was not specifically studied in women with anemia.

§Compared with nearly 2 in 10 women taking placebo.

In Trial 2, 50% of the 48 women taking ORIAHNN with a baseline hemoglobin of ≤10.5 g/dL achieved an increase of >2 g/dL in Hgb at Month 6 compared with 21% of the 24 women taking placebo.

In Trial 1, 62% of the 52 women taking ORIAHNN with a baseline hemoglobin of ≤10.5 g/dL achieved an increase of >2 g/dL in Hgb at Month 6 compared with 16% of the 31 women taking placebo.

Ready to talk with your doctor about ORIAHNN?

ORIAHNN was studied in a broad range of women

The 790 women who participated in the ORIAHNN clinical trials all experienced heavy periods due to uterine fibroids. Here’s a look at their diverse characteristics: